JP2007509067A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509067A5
JP2007509067A5 JP2006535452A JP2006535452A JP2007509067A5 JP 2007509067 A5 JP2007509067 A5 JP 2007509067A5 JP 2006535452 A JP2006535452 A JP 2006535452A JP 2006535452 A JP2006535452 A JP 2006535452A JP 2007509067 A5 JP2007509067 A5 JP 2007509067A5
Authority
JP
Japan
Prior art keywords
epha2
subject
immune response
response against
expressing cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006535452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/034694 external-priority patent/WO2005037233A2/en
Publication of JP2007509067A publication Critical patent/JP2007509067A/ja
Publication of JP2007509067A5 publication Critical patent/JP2007509067A5/ja
Abandoned legal-status Critical Current

Links

JP2006535452A 2003-10-15 2004-10-15 リステリアに基づくEphA2ワクチン Abandoned JP2007509067A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US51191903P 2003-10-15 2003-10-15
US51171903P 2003-10-15 2003-10-15
US53266603P 2003-12-24 2003-12-24
US55663104P 2004-03-26 2004-03-26
US61547004P 2004-10-01 2004-10-01
US61754404P 2004-10-07 2004-10-07
PCT/US2004/034694 WO2005037233A2 (en) 2003-10-15 2004-10-15 Listeria-based epha2 vaccines

Publications (2)

Publication Number Publication Date
JP2007509067A JP2007509067A (ja) 2007-04-12
JP2007509067A5 true JP2007509067A5 (enExample) 2007-12-06

Family

ID=34468559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006535452A Abandoned JP2007509067A (ja) 2003-10-15 2004-10-15 リステリアに基づくEphA2ワクチン

Country Status (7)

Country Link
US (1) US20050281783A1 (enExample)
EP (1) EP1682173A4 (enExample)
JP (1) JP2007509067A (enExample)
KR (1) KR20060130038A (enExample)
AU (1) AU2004281834A1 (enExample)
CA (1) CA2542631A1 (enExample)
WO (1) WO2005037233A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7612162B2 (en) * 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US20120052080A1 (en) * 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
AU2005295158A1 (en) * 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
US20060122138A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Modulators of EphA2 and EphrinA1 for the treatment of fibrosis-related disease
DE102006004612A1 (de) * 2006-02-01 2007-08-16 Ralf Dr. med. Jochem Therapeutische Zusammensetzung zur Vorbeugung und Bekämpfung von Knochenmetastasen
EP2860253B1 (en) 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
WO2007103261A2 (en) * 2006-03-01 2007-09-13 Medimmune, Inc. Listeria-based epha2 immunogenic compositions
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2061800B1 (en) * 2006-08-15 2015-07-29 The Trustees of the University of Pennsylvania Compositions comprising hmw-maa and fragments thereof, and methods of use thereof
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
WO2009044272A2 (en) * 2007-10-04 2009-04-09 000'npt Mbp Gormezis' Laser-based vaccine adjuvants
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20140234370A1 (en) * 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2010071769A2 (en) * 2008-12-12 2010-06-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Chimeric l. monocytogens in1b protein
WO2010102140A1 (en) 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
EP2498808A4 (en) * 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US10016617B2 (en) * 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP5977737B2 (ja) 2010-05-23 2016-08-24 アデュロ バイオテック 癌の補助薬物療法でリステリアを使用する方法および組成物
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
EP2446895A1 (en) * 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
EP2764082B1 (en) 2011-10-04 2018-05-23 Expression Pathology, Inc. Srm/mrm assay for the ephrin type-a receptor 2 protein
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
MX2016014367A (es) * 2014-05-02 2017-06-30 Univ Pennsylvania Combinación de inmunoterapia y radioterapia para el tratamiento de canceres positivos a her-2.
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
EP3364986B1 (en) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inactivated cryo-poor plasma and methods of use thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EA201991506A1 (ru) 2016-12-23 2020-01-23 Сирус Корпорейшн Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CN110573169B (zh) 2017-03-03 2024-10-01 塞鲁斯公司 制备病原体灭活的血小板组合物的试剂盒和方法
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的系统和方法
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
CN114173842A (zh) 2019-06-22 2022-03-11 塞鲁斯公司 生物流体处理系统
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
CN114015644A (zh) * 2021-11-05 2022-02-08 成都生物制品研究所有限责任公司 一种单一病毒收获液的生产方法
CN114848654B (zh) * 2022-04-18 2024-04-05 武汉大学 阿司匹林在制备用于引起肿瘤免疫原性细胞死亡的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
DE60045075D1 (de) * 1999-08-17 2010-11-18 Purdue Research Foundation Anti-epha2 antikörper als krebsdiagnostikum
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same

Similar Documents

Publication Publication Date Title
JP2008505857A5 (enExample)
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2012126742A5 (enExample)
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2009039854A8 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
JP2006512391A5 (enExample)
JP2007517055A5 (enExample)
JP2011136997A5 (enExample)
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
JP2007527914A5 (enExample)
WO2010066418A8 (de) Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
JP2007520566A5 (enExample)
WO2006026394A3 (en) Method of eliciting an immune response against hiv
HRP20191291T1 (hr) Imunogeni pripravak
WO2008090223A3 (en) Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
JP2010532766A5 (enExample)
EA201591663A1 (ru) Бесклеточная противококлюшная вакцина
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
JP2012528856A5 (enExample)
JP2011521967A5 (enExample)
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use